GFAP and Alzheimer disease: MeCP2 phosphorylation coupled to AD injury-induced DNA demethylation in Gfap, Nestin, and DCX promoters causing a loss of MeCP2 binding to its cellular targets, thereby relieving transcriptional repression, permitting gene activation.